Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: a comparative study of three definitions.

Miyake M, Tanaka N, Asakawa I, Owari T, Hori S, Morizawa Y, Nakai Y, Inoue T, Anai S, Torimoto K, Hasegawa M, Fujii T, Konishi N, Fujimoto K.

Prostate Int. 2019 Jun;7(2):47-53. doi: 10.1016/j.prnil.2018.04.005. Epub 2018 May 5.

2.

Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy.

Ghadjar P, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Höcht S, Hölscher T, Sedlmayer F, Wenz F, Zips D, Wiegel T; Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party Radiation Oncology of the German Cancer Society (DKG-ARO).

Strahlenther Onkol. 2018 Jul;194(7):619-626. doi: 10.1007/s00066-018-1269-3. Epub 2018 Jan 30. Review.

PMID:
29383406
3.

Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study.

Miyake M, Tanaka N, Asakawa I, Morizawa Y, Anai S, Torimoto K, Aoki K, Yoneda T, Hasegawa M, Konishi N, Fujimoto K.

Radiat Oncol. 2014 Oct 20;9:208. doi: 10.1186/1748-717X-9-208.

4.

Treatment Outcomes from 68Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET.

Emmett L, van Leeuwen PJ, Nandurkar R, Scheltema MJ, Cusick T, Hruby G, Kneebone A, Eade T, Fogarty G, Jagavkar R, Nguyen Q, Ho B, Joshua AM, Stricker P.

J Nucl Med. 2017 Dec;58(12):1972-1976. doi: 10.2967/jnumed.117.196683. Epub 2017 Jul 26.

5.

68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.

Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG.

J Nucl Med. 2018 Feb;59(2):230-237. doi: 10.2967/jnumed.117.201749. Epub 2017 Nov 9.

6.

Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

Lee EK, Mui WH, Chan AW, Tung Y, Wong FC.

Hong Kong Med J. 2018 Jun;24(3):218-225. doi: 10.12809/hkmj176888. Epub 2018 May 21.

7.

Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.

Gandaglia G, Fossati N, Karnes RJ, Boorjian SA, Colicchia M, Bossi A, Seisen T, Cozzarini C, Di Muzio N, Noris Chiorda B, Zaffuto E, Wiegel T, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A.

Eur Urol. 2018 Apr;73(4):512-518. doi: 10.1016/j.eururo.2017.11.020. Epub 2017 Dec 8.

PMID:
29229176
8.

Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy.

Lee RJ, Tzou KS, Heckman MG, Hobbs CJ, Rawal B, Diehl NN, Peterson JL, Paryani NN, Ko SJ, Daugherty LC, Vallow LA, Wong W, Schild S, Pisansky TM, Buskirk SJ.

BJU Int. 2016 Aug;118(2):236-42. doi: 10.1111/bju.13229. Epub 2015 Aug 22.

9.

Salvage radiotherapy for biochemical recurrence after radical prostatectomy: does the outcome depend on the prostate cancer characteristics?

Viani GA, Hamamura AC, Correa AC, de Arruda FT.

Int Braz J Urol. 2019 Mar-Apr;45(2):237-245. doi: 10.1590/S1677-5538.IBJU.2018.0039.

10.

Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy.

Ying J, Wang CJ, Yan J, Liauw SL, Straka C, Pistenmaa D, Xie XJ, Lotan Y, Roehrborn C, Kim DN.

Am J Clin Oncol. 2017 Dec;40(6):612-620. doi: 10.1097/COC.0000000000000207.

PMID:
26165416
11.

Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.

Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T, Briganti A.

Eur Urol. 2016 Apr;69(4):728-733. doi: 10.1016/j.eururo.2015.10.009. Epub 2015 Oct 21.

PMID:
26497924
12.

Impact of Gleason pattern 5 including tertiary pattern 5 on outcomes of salvage treatment for biochemical recurrence in pT2-3N0M0 prostate cancer.

Taguchi S, Shiraishi K, Fukuhara H, Nakagawa K, Morikawa T, Naito A, Kakutani S, Takeshima Y, Miyazaki H, Nakagawa T, Fujimura T, Kume H, Homma Y.

Int J Clin Oncol. 2016 Oct;21(5):975-980. Epub 2016 Apr 20.

PMID:
27098807
13.

Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer.

Stish BJ, Pisansky TM, Harmsen WS, Davis BJ, Tzou KS, Choo R, Buskirk SJ.

J Clin Oncol. 2016 Nov 10;34(32):3864-3871. doi: 10.1200/JCO.2016.68.3425.

PMID:
27480153
14.

Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.

Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, Supiot S, Bosset M, Lagrange JL, Beckendorf V, Lesaunier F, Dubray B, Wagner JP, N'Guyen TD, Suchaud JP, Créhange G, Barbier N, Habibian M, Ferlay C, Fourneret P, Ruffion A, Dussart S.

Lancet Oncol. 2016 Jun;17(6):747-756. doi: 10.1016/S1470-2045(16)00111-X. Epub 2016 May 6. Erratum in: Lancet Oncol. 2016 Jun;17 (6):e223. Erratum in: Lancet Oncol. 2019 Jun;20(6):e293.

PMID:
27160475
15.

Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy.

Mir MC, Li J, Klink JC, Kattan MW, Klein EA, Stephenson AJ.

Eur Urol. 2014 Aug;66(2):204-10. doi: 10.1016/j.eururo.2013.08.022. Epub 2013 Aug 20.

PMID:
24007712
16.

Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure.

Kabarriti R, Ohri N, Hannan R, Tishbi N, Baliga S, McGovern KP, Mourad WF, Ghavamian R, Kalnicki S, Guha C, Garg MK.

Pract Radiat Oncol. 2014 Nov-Dec;4(6):409-14. doi: 10.1016/j.prro.2014.01.002. Epub 2014 Feb 22.

PMID:
25407863
17.

Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression.

Lohm G, Neumann K, Budach V, Wiegel T, Hoecht S, Gollrad J.

Strahlenther Onkol. 2018 Apr;194(4):325-332. doi: 10.1007/s00066-017-1247-1. Epub 2017 Dec 18.

PMID:
29255924
18.

Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.

Cortés-González JR, Castellanos E, Sandberg K, Eriksson MH, Wiklund P, Carlsson S, Cohn-Cedermark G, Harmenberg U, Gustafsson O, Levitt SH, Lennernäs B, Brandberg Y, Márquez M, Kälkner KM, Nilsson S.

Int J Oncol. 2013 Jan;42(1):109-17. doi: 10.3892/ijo.2012.1694. Epub 2012 Nov 13.

PMID:
23151842
19.

Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.

Goenka A, Magsanoc JM, Pei X, Schechter M, Kollmeier M, Cox B, Scardino PT, Eastham JA, Zelefsky MJ.

Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):112-8. doi: 10.1016/j.ijrobp.2011.10.077. Epub 2012 Jan 31.

PMID:
22300563
20.

Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy.

Yang DD, Muralidhar V, Mahal BA, Nezolosky MD, Labe SA, Vastola ME, Boldbaatar N, King MT, Martin NE, Orio PF 3rd, Choueiri TK, Trinh QD, Den RB, Spratt DE, Hoffman KE, Feng FY, Nguyen PL.

Urol Oncol. 2017 Sep;35(9):542.e25-542.e32. doi: 10.1016/j.urolonc.2017.04.018. Epub 2017 May 19.

PMID:
28533151

Supplemental Content

Support Center